Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “mucosal immunization”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 865 records · Page 48Linked to original sources

Fetal intestinal transplant model for mucosal immune responses.

A rat fetal intestinal transplant model was developed for long-term study of intestinal immune responses. For the model, fetal small intestine is transplanted into the dorsal subcutaneous tissue of syngeneic adults and allowed to mature, providing an accessible site, isolated from the intestinal stream. We previously demonstrated normal histologic maturation of the transplant. Specific antibody-producing cells appeared in the lamina propria of both transplant and native in situ intestine following intraluminal immunization of the transplant with cholera toxin, and conversely, in transplants after immunization of in situ intestine. An enterointestinal lymphocyte migratory pathway (originating in intestine and migrating to another region of the intestine) was thus demonstrated unequivocally. We found a bacterial flora in the transplant, and showed normal villus morphology in scanning electron microscopy. Less than 200 pg, i.e., a 10(-7) fraction, of 2 mg macromolecular lipopolysaccharide placed in the transplant lumen was absorbed per plasma lipopolysaccharide half-life. Immunization of the transplant with cholera toxin resulted in specific IgA and IgG antibody in the transplant lumen and in bile, and specific IgG, but not IgA, antibody in serum. A second dose of antigen gave an anamnestic rise in intra-transplant antibody. Intestinal immune tolerance was also demonstrated: sheep red blood cells (SRBC) administered into the transplant for 7 days suppressed splenic IgM plaque forming responses to subsequent intraperitoneal challenge with SRBC. These studies further demonstrate that the fetal intestinal transplant behaves immunologically like native intestine, and therefore provides a useful model for investigation of the intestinal immune system.

Animals↗

The development of mucosal immunity in guinea pig middle ears.

Recent studies have suggested to us that the middle ear is an organ capable of responding immunologically to antigenic substance. However, it is still not known when and how the middle ear starts to provide the immunologic defense system. To clarify this, we investigated immunoglobulin forming cells of different classes and secretory proteins, such as secretory component and lactoferrin, in the mucous membrane of eustachian tube and tympanic bulla of 20 developing and 5 normal adult guinea pigs by the use of a direct immunofluorescence technique. Other organs, such as nose, larynx, trachea, small intestine, spleen and lymph node were also subjected to this investigation. Changes in the middle ear mucosa were also observed after antigenic challenges directly to the tympanic cavity of 6 developing and 39 adult guinea pigs. IgA and IgM forming cells began to appear in the tubal mucosa on 7th postnatal day, wile it was scarcely possible to find IgG1 and IgG2 forming cells in developing guinea pigs. Immunoglobulin forming cells of all classes increased in the middle ear mucosa after the antigenic stimuli. Results of this study showed that local synthesis of IgA, as well as other classes, is latent in the middle ear, that the middle ear of immature animals is vulnerable to antigenic stimuli, and that the middle ear of developing animals possesses potential immune responsiveness.

Animals↗

Conversion of orally induced suppression of the mucosal immune response to ovalbumin into stimulation by conjugating ovalbumin to cholera toxin or its B subunit.

Oral pretreatment of mice with ovalbumin (OVA) not only suppressed a subsequently induced systemic immune response ('oral tolerance') but also suppressed, even more effectively, a subsequently induced intestinal IgA response. In contrast, pretreatment with OVA conjugated to cholera toxin (CT) or its B subunit (CTB) resulted in a stimulative effect. The stimulative effect was enhanced when unconjugated OVA and polymerized OVA were removed from the OVA-CT (B) conjugate mixtures by affinity chromatography. Thus, the effect of oral pretreatment depends on the balance between tolerizing and stimulating components in the conjugate mixture. As OVA-CTB conjugates were at least as effective as OVA-CT conjugates in stimulation of the intestinal immune response, we concluded that the ability of the OVA conjugates to bind to the intestinal mucosa is a prerequisite in inducing the stimulative effect. These observations further demonstrate that conjugation of a protein antigen to an appropriate carrier can convert the nature of the immunization from suppressive into stimulative.

Administration, Oral↗

Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection.

In a phase I clinical trial to test safety and patient acceptance 25 women with a history of recurrent urinary tract infections but no identifiable anatomic abnormality received a multivalent vaccine instilled into the vagina. The vaccine contained 6 heat-killed Escherichia coli strains and 4 nonE. coli uropathogens. Only minimal adverse reactions were observed in the 5-month period following immunization. Total vaginal and urinary IgG and IgA increased significantly (p < 0.01 by repeated measures analysis of variance). Serum antibodies to some of the nonE. coli strains but not to the E. coli strains increased after vaginal immunization. While efficacy is yet to be shown, this study indicates that this vaginally applied urinary tract infection vaccine is well tolerated, and capable of increasing vaginal and urinary antibody.

Adjuvants, Immunologic↗

Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease.

Emphasis is now being placed upon obtaining a better understanding of the regulatory cytokines that normally downregulate acute intestinal inflammation. These inhibitory cytokines appear to be missing or not functioning properly in patients with inflammatory bowel disease (IBD), thereby leading to perpetuation of inflammation. As we obtain an increased understanding of immune and inflammatory regulatory processes in the intestine, we will be able to devise better future therapeutic strategies for use in our IBD patients.

Colitis, Ulcerative↗